查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1588912

單細胞基因組定序的全球市場

Single-Cell Genome Sequencing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 89 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球單細胞基因組定序市場將達到 72 億美元

全球單細胞基因組定序市場預計 2023 年為 29 億美元，預計到 2030 年將達到 72 億美元，2023-2030 年分析期間複合年成長率為 13.6%。細胞基因組定序設備是本報告分析的細分市場之一，複合年成長率為 14.2%，預計到分析期結束時將達到 45 億美元。分析期間，細胞基因組定序試劑領域的複合年成長率預計為 12.6%。

美國市場預計8.035億美元，中國預期複合年成長率12.8%

預計 2023 年美國單細胞基因組定序市場規模將達 8.035 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達11億美元，2023-2030年分析期間複合年成長率為12.8%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 11.9% 和 11.4%。在歐洲，德國的複合年成長率預計約為 9.6%。

全球單細胞基因組定序市場—主要趨勢與促進因素總結

單細胞基因組定序如何推進基因組研究？

單細胞基因組定序是一項尖端技術，使科學家能夠分析單一細胞的遺傳物質，從而在粒度層面上深入了解細胞異質性、基因表現和疾病機制。這項技術對於理解複雜的生物系統（例如癌症進展、免疫反應、神經系統疾病和發育生物學）至關重要。透過讓研究人員能夠識別組織內的遺傳變異和細胞多樣性，單細胞基因組定序可以更深入地了解疾病途徑，從而實現更有效的診斷、標靶治療和個人化治療，從而形成一種醫療方法。隨著精準醫療需求的增加，單細胞基因組定序持續徹底改變基因組學研究和臨床應用。

單細胞基因組定序市場的關鍵部分是什麼？

關鍵技術包括微流體、次世代定序儀（NGS）和定量PCR，其中次世代定序儀因其高通量、準確性和全面的資料輸出而佔據最大的市場佔有率。主要應用是癌症基因組學、免疫學、幹細胞研究和神經生物學，其中癌症基因組學成為一個重要的領域，因為單細胞測序為腫瘤異質性和抗藥性提供了重要的見解。最終用戶包括研究機構、臨床實驗室和製藥公司，研究機構專注於探索遺傳變異和細胞多樣性，使市場成為主要企業。

單細胞基因組定序如何應用於研究和醫學？

在癌症研究中，單細胞基因組定序用於識別基因突變、腫瘤進化和抗藥性機制，支持標靶治療和個人化治療策略的開發。免疫學研究利用單細胞定序來了解免疫細胞多樣性、追蹤免疫反應並識別自體免疫疾病和疫苗開發的生物標記。幹細胞研究利用該技術來分析細胞分化、譜系追蹤和可再生，有助於推進組織工程和再生醫學。在神經生物學中，單細胞定序可以深入了解神經發育障礙、突觸功能和神經元多樣性的遺傳基礎，有助於更深入了解阿茲海默症和自閉症等疾病。此外，單細胞定序的臨床應用正在擴大，特別是在產前診斷和罕見疾病鑑定方面，準確的基因分析至關重要。

推動單細胞基因組定序市場成長的因素有哪些？

單細胞基因組定序市場的成長受到多種因素的推動，包括對依賴細胞層面的詳細遺傳資訊來開發個人化治療的精準醫學的需求不斷成長。定序技術的進步，例如更高的通量、更高的準確性和更低的成本，使得單細胞定序在研究和臨床環境中更容易實現。對癌症基因組學、免疫治療和神經退化性疾病研究的日益關注正在加速單細胞基因組測序的採用，因為它可以深入了解細胞異質性和疾病機制。支持基因組學研究的政府資助和舉措，加上研究機構和製藥公司之間不斷加強的合作，正在進一步推動市場成長。此外，人工智慧和生物資訊學在資料分析中的整合增強了對複雜序列資料的解釋，並支持基因組學研究的廣泛應用。

受訪企業範例（33家知名企業）

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI
  • Bio-Rad Laboratories
  • DNA Electronics Ltd.
  • F Hoffmann-La Roche Ltd.
  • Fluidigm
  • Illumina, Inc.
  • Johnson & Johnson
  • Novogene
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Zephyrus Biosciences Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP22773

Global Single-Cell Genome Sequencing Market to Reach US$7.2 Billion by 2030

The global market for Single-Cell Genome Sequencing estimated at US$2.9 Billion in the year 2023, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2023-2030. Cell Genome Sequencing Instruments, one of the segments analyzed in the report, is expected to record a 14.2% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Cell Genome Sequencing Reagents segment is estimated at 12.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$803.5 Million While China is Forecast to Grow at 12.8% CAGR

The Single-Cell Genome Sequencing market in the U.S. is estimated at US$803.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.9% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Global Single-Cell Genome Sequencing Market - Key Trends and Drivers Summarized

How Is Single-Cell Genome Sequencing Advancing Genomics Research?

Single-cell genome sequencing is a cutting-edge technique that allows scientists to analyze the genetic material of individual cells, providing insights into cellular heterogeneity, gene expression, and disease mechanisms at a granular level. This technology is pivotal in understanding complex biological systems, including cancer progression, immune responses, neurological disorders, and developmental biology. By enabling researchers to identify genetic variations and cellular diversity within tissues, single-cell genome sequencing offers a deeper understanding of disease pathways, leading to more effective diagnostics, targeted therapies, and personalized medicine approaches. As the demand for precision medicine grows, single-cell genome sequencing continues to revolutionize genomics research and clinical applications.

What Are the Key Segments in the Single-Cell Genome Sequencing Market?

Key technologies include microfluidics, next-generation sequencing (NGS), and quantitative PCR, with next-generation sequencing holding the largest market share due to its high throughput, accuracy, and comprehensive data output. Major applications cover cancer genomics, immunology, stem cell research, and neurobiology, with cancer genomics representing a significant segment as single-cell sequencing provides critical insights into tumor heterogeneity and drug resistance. End-users encompass research institutes, clinical laboratories, and pharmaceutical companies, with research institutes leading the market due to their focus on exploring genetic variations and cellular diversity.

How Is Single-Cell Genome Sequencing Being Used Across Research and Medicine?

In cancer research, single-cell genome sequencing is used to identify genetic mutations, tumor evolution, and drug resistance mechanisms, supporting the development of targeted therapies and personalized treatment strategies. Immunology studies leverage single-cell sequencing to understand immune cell diversity, track immune responses, and identify biomarkers for autoimmune diseases and vaccine development. Stem cell research uses this technology to analyze cell differentiation, lineage tracing, and regenerative potential, aiding in advancements in tissue engineering and regenerative medicine. In neurobiology, single-cell sequencing provides insights into the genetic basis of neurodevelopmental disorders, synaptic functions, and neuron diversity, contributing to a better understanding of diseases like Alzheimer's and autism. Additionally, clinical applications of single-cell sequencing are expanding, particularly in prenatal diagnostics and rare disease identification, where accurate genetic profiling is crucial.

What Factors Are Driving the Growth in the Single-Cell Genome Sequencing Market?

The growth in the Single-Cell Genome Sequencing market is driven by several factors, including increasing demand for precision medicine, which relies on detailed genetic information at the cellular level to develop personalized treatments. Advancements in sequencing technologies, such as higher throughput, improved accuracy, and cost reductions, have made single-cell sequencing more accessible across research and clinical settings. The expanding focus on cancer genomics, immunotherapy, and neurodegenerative disease research has accelerated the adoption of single-cell genome sequencing, as it provides insights into cellular heterogeneity and disease mechanisms. Government funding and initiatives supporting genomics research, combined with growing collaborations between research institutes and pharmaceutical companies, have further fueled market growth. Additionally, the integration of AI and bioinformatics in data analysis has enhanced the interpretation of complex sequencing data, supporting broader applications in genomics research.

Select Competitors (Total 33 Featured) -

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI
  • Bio-Rad Laboratories
  • DNA Electronics Ltd.
  • F Hoffmann-La Roche Ltd.
  • Fluidigm
  • Illumina, Inc.
  • Johnson & Johnson
  • Novogene
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Zephyrus Biosciences Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Single-Cell Genome Sequencing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Precision Medicine and Genomics Research Spurs Growth in Single-Cell Genome Sequencing Market
    • Technological Advancements in Sequencing Accuracy, Speed, and Data Analysis Strengthen Business Case for Adoption
    • Growing Focus on Cancer Genomics, Immunology, and Rare Disease Research Expands Addressable Market
    • Increasing Adoption of Sequencing in Stem Cell Research, Neuroscience, and Developmental Biology Expands Market Opportunities
    • Technological Innovations in Library Preparation, Microfluidics, and Bioinformatics Propel Market Expansion
    • Rising Focus on Complying with Ethical Guidelines, Informed Consent, and Data Privacy Drives Demand for Single-Cell Sequencing
    • Growing Use of Single-Cell Sequencing in Drug Discovery, Tumor Heterogeneity Studies, and Biomarker Discovery Expands Market Potential
    • Rising Adoption of Sequencing in Non-Invasive Prenatal Testing, Liquid Biopsies, and Cell-Free DNA Analysis Expands Addressable Market
    • Technological Advancements in AI-Powered Genomics, Machine Learning Algorithms, and Cloud Sequencing Propel Market Growth
    • Increasing Focus on Integrating Single-Cell Sequencing with Multi-Omics, CRISPR, and Synthetic Biology Drives Adoption
    • Rising Demand for Sequencing in Infectious Disease Genomics, Microbiome Research, and Immune Profiling Strengthens Global Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Single-Cell Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Single-Cell Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Academic & Research Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Academic & Research Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Biotech & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for qPCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Microarray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Microarray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Microarray by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for MDA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for MDA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for MDA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 37: World Single-Cell Genome Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • JAPAN
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • CHINA
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • EUROPE
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Single-Cell Genome Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Single-Cell Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • FRANCE
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • GERMANY
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Single-Cell Genome Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Product - Instruments and Reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Single-Cell Genome Sequencing by Product - Instruments and Reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Single-Cell Genome Sequencing by Product - Percentage Breakdown of Value Sales for Instruments and Reagents for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Single-Cell Genome Sequencing by End-Use - Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Single-Cell Genome Sequencing by End-Use - Percentage Breakdown of Value Sales for Clinics, Other End-Uses, Academic & Research Labs and Biotech & Biopharma Companies for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Single-Cell Genome Sequencing by Technology - NGS, PCR, qPCR, Microarray and MDA Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Single-Cell Genome Sequencing by Technology - Percentage Breakdown of Value Sales for NGS, PCR, qPCR, Microarray and MDA for the Years 2014, 2024 & 2030

IV. COMPETITION